Exelixis Inc (EXEL) Stock Price, Quote & News

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 7000

Fax: 650 837 8300

Website: www.exelixis.com

Address:

1851 Harbor Bay Parkway, Alameda, United States

StocktwitsNews Sep. 11 at 8:19 PM

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term $EXEL $IJH $VTI https://stocktwits.com/news/equity/markets/exel-stock-slides-after-fda-adds-three-months-to-cancer-drug-review-william-blair-sees-more-swings-in-near-term/cZtXM0eRBbg

0 · Reply

svb64 Sep. 11 at 2:52 PM

$EXEL gov/FDA takes its time. A delay is a delay nothing else.

0 · Reply

notreload_ai Sep. 11 at 12:26 PM

FDA adds three months to its review of $EXEL zanzalintinib plus Tecentriq for metastatic colorectal cancer after a major amendment. New date: March 3, 2027. https://notreload.xyz/xy/fda-extends-exelixis-crc-combo-review-to-march-2027/

0 · Reply

OpenOutcrier Sep. 11 at 12:12 PM

$EXEL (-3.2% pre) FDA Extends Review Timeline for Exelixis Cancer Drug https://ooc.bz/l/113915

0 · Reply

Jimmy34 Sep. 11 at 12:05 PM

$EXEL this request doesn’t affect the approval of the drug it generally speaking it just extends the breath of the label for the drug It’s not a negative it’s actually a positive it’s gonna lead to an approval with extending the breath of the label based upon side effects

0 · Reply

DonCorleone77 Sep. 11 at 11:30 AM

$EXEL Exelixis says FDA extends review period for zanzalintinib NDA by three months Exelixis announced that on September 10, the U.S. Food and Drug Administration notified Exelixis that it had extended the review period for Exelixis' new drug application for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer by three months. In response to an FDA information request, Exelixis had submitted updated safety and efficacy data, which the FDA has deemed a major amendment. The updated Prescription Drug User Fee Act action date is March 3, 2027.

0 · Reply

OtherOtttawaGuy Sep. 8 at 11:24 PM

$EXEL Google AI Redpone to: "Tiawsn, Excelixis citizens petitoon" The U.S. Food and Drug Administration (FDA) completely rejected a Citizen Petition filed by US-based pharmaceutical company Exelixis against the Taiwanese pharmaceutical firm, Handa Pharmaceuticals. [1, 2] Concurrently, on September 3, 2026, Handa's novel formulation cancer drug, HND-039 (Omcazio), received final FDA approval. [1] Background of the Dispute The Petition: In April 2026, Exelixis (the originator of the blockbuster cancer drug Cabometyx) filed a 505(q) Citizen Petition requesting that the FDA refuse or delay approval for Handa's drug. Exelixis claimed Handa's product required more clinical data regarding safety and effectiveness. [1, 2] The Patent Lawsuit: Alongside the FDA petition, Exelixis filed patent infringement lawsuits to block Handa's copycat drug. However, on August 27, 2026, Exelixis voluntarily dismissed its patent lawsuit against Handa. [1, 2]

1 · Reply

Yeaboiii Sep. 8 at 5:54 PM

$EXEL Has anyone seen this? Does it make sense? Chatgpt says it checks out? https://www.reddit.com/r/biotech_stocks/s/8Qs2pqa8sC

1 · Reply

polishsmokestack Sep. 3 at 12:36 PM

$BFRI Institutional ownership is only 17%. Alot of funds cannot purchase equities less than $5 and higher. If approved this will start to bring attention. I wonder where the price will go to once tutes start accumulating. I bought $EXEL 7 years ago. Its tute ownership is around the 80% range.

1 · Reply

zero_vector Sep. 3 at 9:41 AM

$EXEL breaking out to all time high

0 · Reply

Market Cap	13.91B
Revenue (ttm)	2.32B
Net Income (ttm)	782.57M
EPS (ttm)	N/A
PE Ratio	18.17
Forward PE	18.00
Profit Margin	33.73%
Debt to Equity Ratio	0.00

Volume	2,916,800
Avg Vol	2,428,164
Day's Range	N/A - N/A
Shares Out	247.78M
Stochastic %K	43%
Beta	0.42
Analysts	Sell
Price Target	$53.44